List of works - Ilaria Iacobucci

A case report of acute myeloid leukemia and neurofibromatosis 1.

scientific article published in June 2013

A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia

scientific article published on December 2012

A novel t(2;10)(q31;p12) balanced translocation in acute myeloid leukemia

scientific article published on November 2012

A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia

scientific article

A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients

scientific article published on 12 July 2011

AICDA expression in BCR/ABL1-positive acute lymphoblastic leukaemia is associated with a peculiar gene expression profile

scientific article published on 31 January 2011

Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia

scientific article

Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role of MPL polymorphisms

scientific article published on 29 December 2012

Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.

scientific article

Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis.

scientific article

Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis

scientific article published on August 2012

Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy

scientific article published on 8 August 2012

B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene.

scientific article

Bellerophontes: an RNA-Seq data analysis framework for chimeric transcripts discovery based on accurate fusion model

scientific article

CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients.

scientific article

Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?

scientific article published on 31 May 2011

Chromothripsis in acute myeloid leukemia: biological features and impact on survival

scientific article published on 23 February 2018

Cisplatin binding to β-lactoglobulin: a structural study

scientific article published on 27 August 2020

Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia

scientific article published on 17 January 2018

Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment

scientific article published in January 2006

Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient

scientific article published on August 2010

Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia

article by Simona Soverini et al published 15 December 2006 in Clinical Cancer Research

Cytogenetic and molecular predictors of outcome in acute lymphocytic leukemia: recent developments

scientific article published on June 2012

Cytoplasmatic compartmentalization by Bcr-Abl promotes TET2 loss-of-function in chronic myeloid leukemia

scientific article

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

scientific article

Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis

scientific article published on 3 May 2010

Deregulation of DUX4 and ERG in acute lymphoblastic leukemia

scientific article published on 24 October 2016

Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia

scientific article published on 29 September 2011

Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group

scientific article

Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia

scientific article

Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia

scientific article

Epigenetically induced ectopic expression of UNCX impairs the proliferation and differentiation of myeloid cells

scientific article

Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance

scientific article

Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib.

scientific article published on April 2008

Flai (fludarabine, cytarabine, idarubicin) plus low-dose gemtuzumab ozogamicin as induction therapy in cd33-positive aml: Final results and long term outcome of a phase ii multicenter clinical trial

scientific article

Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome

scientific article published on 26 March 2008

Genetic Basis of Acute Lymphoblastic Leukemia

scientific article published on 13 February 2017

Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia

scientific article

High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults

scientific article published on 21 November 2016

IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia

scientific article

IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report

scientific article

Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute

scientific article

Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method

article published in 2008

Imatinib mesylate for the treatment of chronic myeloid leukemia

scientific article published on June 2008

Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party

scientific article published on 01 January 2007

Imputation reliability on DNA biallelic markers for drug metabolism studies

scientific article

In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia

scientific article

Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.

scientific article published on 26 May 2009

Intermittent targeting as a tool to minimize toxicity of tyrosine kinase inhibitor therapy

scientific article

Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase

scientific article published in November 2007

Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.

scientific article published in January 2008

Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib.

scientific article

Modulation of Amyloidogenic Peptide Aggregation by Photoactivatable CO-Releasing Ruthenium(II) Complexes

scientific article published on 29 July 2020

Monitoring BCR-ABL transcript levels by real-time quantitative polymerase chain reaction: a linear regression equation to convert from BCR-ABL/B2M ratio to estimated BCR-ABL/ABL ratio

scientific article

Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management

scientific article published on December 2006

New label-free methods for protein relative quantification applied to the investigation of an animal model of Huntington Disease

scientific article published on 04 September 2020

New mechanisms of resistance in Philadelphia chromosome acute lymphoblastic leukemia

scientific article published on June 2009

New targets for Ph+ leukaemia therapy

scientific article published on September 2009

Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance

scientific article published on June 2007

Osteopontin binds ICOSL promoting tumor metastasis

scientific article published on 26 October 2020

Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis

scientific article

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.

scientific article published on 9 July 2009

Platinum(II) , Complexes Inhibit the Aggregation of Amyloid Model Systems

scientific article published in 2019

Posterior reversible encephalopathy syndrome in a B-cell acute lymphoblastic leukemia young adult patient treated with a pediatric-like chemotherapeutic schedule

scientific article published on August 2014

Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function

scientific article published on 20 July 2009

Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia

scientific article published on 01 November 2006

Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia

scientific article published on 11 July 2016

Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes

scientific article published on 17 April 2013

Protein tyrosine phosphatase receptor type {gamma} is a functional tumor suppressor gene specifically downregulated in chronic myeloid leukemia

scientific article published on 19 October 2010

Rationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment

scientific article

Recurrent Gastrointestinal Hemorrhage in Treatment with Dasatinib in a Patient Showing SMAD4 Mutation with Acute Lymphoblastic Leukemia Philadelphia Positive and Juvenile Polyposis Hereditary Hemorrhagic Telangiectasia Syndrome

scientific article

Relationship between genome and epigenome--challenges and requirements for future research

scientific article published on 18 June 2014

Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain

scientific article published on 01 March 2007

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party

scientific article published on 11 February 2009

Single Nucleotide Polymorphisms as Genomic Markers for High-Throughput Pharmacogenomic Studies

scientific article published in January 2016

Structural determinants in ApoA-I amyloidogenic variants explain improved cholesterol metabolism despite low HDL levels

scientific article published on 5 September 2017

Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia

scientific article published in December 2009

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia

scientific article

Targeting CDK6 and BCL2 exploits the "MYB addiction" of Ph+ acute lymphoblastic leukemia

scientific article published on 12 December 2017

Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia

scholarly article by Andrea Ghelli Luserna Di Rorà published in August 2018

Targeting precursor BCR signaling in ALL.

scientific article published in March 2017

Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients

scientific article published on 12 February 2016

The B cell mutator AID promotes B lymphoid blast crisis and drug resistance in chronic myeloid leukemia

scientific article

The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias

scientific article

The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party

scientific article

The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study

scientific article published on 01 August 2007

The genetic basis and cell of origin of mixed phenotype acute leukaemia

scientific article published in Nature

The hidden genomic landscape of acute myeloid leukemia: subclonal structure revealed by undetected mutations

scientific article

The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase

scientific article

Three novel fusion transcripts of the paired box 5 gene in B-cell precursor acute lymphoblastic leukemia

scientific article published on 10 October 2014

Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response

scientific article published in February 2009

Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia

scientific article published on February 2016

Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response

scientific article published on 18 February 2014

Use of single nucleotide polymorphism array technology to improve the identification of chromosomal lesions in leukemia

scientific article

What Antarctic Plants Can Tell Us about Climate Changes: Temperature as a Driver for Metabolic Reprogramming

scientific article published in 2021

Zinc-finger transcription factor slug contributes to the survival advantage of chronic myeloid leukemia cells

scientific article published on 11 April 2010

c-Abl and Src-family kinases cross-talk in regulation of myeloid cell migration

scientific article published on January 2010

List of works by Ilaria Iacobucci

A case report of acute myeloid leukemia and neurofibromatosis 1.

A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia

A novel t(2;10)(q31;p12) balanced translocation in acute myeloid leukemia

A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia

A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients

AICDA expression in BCR/ABL1-positive acute lymphoblastic leukaemia is associated with a peculiar gene expression profile

Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia

Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role of MPL polymorphisms

Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.

Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis.

Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis

Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy

B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene.

Bellerophontes: an RNA-Seq data analysis framework for chimeric transcripts discovery based on accurate fusion model

CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients.

Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?

Chromothripsis in acute myeloid leukemia: biological features and impact on survival

Cisplatin binding to β-lactoglobulin: a structural study

Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia

Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment

Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient

Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia

Cytogenetic and molecular predictors of outcome in acute lymphocytic leukemia: recent developments

Cytoplasmatic compartmentalization by Bcr-Abl promotes TET2 loss-of-function in chronic myeloid leukemia

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis

Deregulation of DUX4 and ERG in acute lymphoblastic leukemia

Developmental origins and impact of BCR-ABL1 fusion and IKZF1 deletions in monozygotic twins with Ph+ acute lymphoblastic leukemia

Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group

Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia

Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia

Epigenetically induced ectopic expression of UNCX impairs the proliferation and differentiation of myeloid cells

Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance

Farnesyltransferase inhibition in hematologic malignancies: the clinical experience with tipifarnib.

Flai (fludarabine, cytarabine, idarubicin) plus low-dose gemtuzumab ozogamicin as induction therapy in cd33-positive aml: Final results and long term outcome of a phase ii multicenter clinical trial

Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome

Genetic Basis of Acute Lymphoblastic Leukemia

Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia

High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults

IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia

IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report

Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute

Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method

Imatinib mesylate for the treatment of chronic myeloid leukemia

Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party

Imputation reliability on DNA biallelic markers for drug metabolism studies

In vitro and in vivo single-agent efficacy of checkpoint kinase inhibition in acute lymphoblastic leukemia

Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.

Intermittent targeting as a tool to minimize toxicity of tyrosine kinase inhibitor therapy

Long-term molecular responses to imatinib in patients with chronic myeloid leukemia: comparison between complete cytogenetic responders treated in early and in late chronic phase

Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.

Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib.

Modulation of Amyloidogenic Peptide Aggregation by Photoactivatable CO-Releasing Ruthenium(II) Complexes

Monitoring BCR-ABL transcript levels by real-time quantitative polymerase chain reaction: a linear regression equation to convert from BCR-ABL/B2M ratio to estimated BCR-ABL/ABL ratio

Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management

New label-free methods for protein relative quantification applied to the investigation of an animal model of Huntington Disease

New mechanisms of resistance in Philadelphia chromosome acute lymphoblastic leukemia

New targets for Ph+ leukaemia therapy

Nilotinib: a novel encouraging therapeutic option for chronic myeloid leukemia patients with imatinib resistance or intolerance

Osteopontin binds ICOSL promoting tumor metastasis

Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.

Platinum(II) , Complexes Inhibit the Aggregation of Amyloid Model Systems

Posterior reversible encephalopathy syndrome in a B-cell acute lymphoblastic leukemia young adult patient treated with a pediatric-like chemotherapeutic schedule

Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function

Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia

Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia

Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes

Protein tyrosine phosphatase receptor type {gamma} is a functional tumor suppressor gene specifically downregulated in chronic myeloid leukemia

Rationale for a pediatric-inspired approach in the adolescent and young adult population with acute lymphoblastic leukemia, with a focus on asparaginase treatment

Recurrent Gastrointestinal Hemorrhage in Treatment with Dasatinib in a Patient Showing SMAD4 Mutation with Acute Lymphoblastic Leukemia Philadelphia Positive and Juvenile Polyposis Hereditary Hemorrhagic Telangiectasia Syndrome

Relationship between genome and epigenome--challenges and requirements for future research

Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain

Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party

Single Nucleotide Polymorphisms as Genomic Markers for High-Throughput Pharmacogenomic Studies

Structural determinants in ApoA-I amyloidogenic variants explain improved cholesterol metabolism despite low HDL levels

Successful combination treatment of clofarabine, cytarabine, and gemtuzumab-ozogamicin in adult refractory B-acute lymphoblastic leukemia

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia

Targeting CDK6 and BCL2 exploits the "MYB addiction" of Ph+ acute lymphoblastic leukemia